Tezacitabine and Oxaliplatin for the Treatment of Patients With Metastatic Colorectal Cancer

Chiron Corporation

Status and phase: Terminated; Phase 2

Conditions: Colorectal Neoplasms

Treatments: Drug: oxaliplatin; Drug: tezacitabine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00051688

TEZ101

Details and patient eligibility

About

The primary purpose of this study is to determine the best dose of tezacitabine when combined with oxaliplatin in patients with metastatic colorectal cancer. This study will also evaluate tumor response to the combination of anti-cancer drugs.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

• Patients with metastatic colorectal adenocarcinoma who have failed one prior course of chemotherapy.
• Patients must have at least one measurable tumor.
• Patients may not have received prior treatment with oxaliplatin.